CFO
VKTX icon

CVA Family Office’s Viking Therapeutics VKTX Stock Holding History

CVA Family Office’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702 Hold
18
– – ﹤0.01% 1686
2026
Q1 		$586 Hold
18
– – ﹤0.01% 1727
2025
Q4 		$633 Hold
18
– – ﹤0.01% 1169
2025
Q3 		$473 Hold
18
– – ﹤0.01% 1259
2025
Q2 		$477 Buy
18
+3
+20% +$79 ﹤0.01% 1246
2025
Q1 		$362 Buy
+15
New +$474 ﹤0.01% 1364
2024
Q4 		– Sell
-10
Closed -$633 – 1343
2024
Q3 		$633 Buy
+10
New +$587 ﹤0.01% 1144

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

CVA Family Office's VKTX Position: Q2 2026 in Review

CVA Family Office held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 18 shares worth $702. The position accounts for ﹤0.01% of the portfolio, ranked #1686.

CVA Family Office first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • CVA Family Office held 18 shares of Viking Therapeutics worth $702 as of Q2 2026.
  • CVA Family Office left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1686 holding.
  • CVA Family Office first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.